Double-blind comparison of sulphonamide-trimethoprim combinations in acute uncomplicated urinary tract infections
- PMID: 389813
- DOI: 10.1007/BF01639020
Double-blind comparison of sulphonamide-trimethoprim combinations in acute uncomplicated urinary tract infections
Abstract
The effects of a twice daily dosage of a combination of 410 mg sulphadiazine + 90 mg trimethoprim (SD + TMP) and 800 mg sulphamethoxazole + 160 mg trimethoprim (SMZ + TMP) were compared in uncomplicated urinary tract infections. All but one patient in each treatment group, i.e. 36 SD + TMP treated and 42 SMZ + TMP treated patients respectively, were cured. The percentage of side-effects related to therapy in the patients receiving the combination with sulphadiazine was 15.1% and in those with sulphamethoxazole 23.7%. Due to the small number tested, however, differences were not statistically different. It is noteworthy that only one of the SD + TMP patients had to stop therapy because of a rash, whereas therapy was stopped for this reason in three of the SMZ + TMP patients. SD + TMP represents a good alternative to SMZ + TMP in the treatment of urinary tract infections.
Similar articles
-
Comparison of sulphadiazine-trimethoprim and sulphamethoxazole-trimethoprim in the treatment of acute respiratory tract infections. Randomized double-blind trial.Chemotherapy. 1980;26(4):297-300. doi: 10.1159/000237920. Chemotherapy. 1980. PMID: 6993109 Clinical Trial.
-
A clinical study of co-trimazine in comparison with co-trimoxazole and sulphalene in urinary tract infections.Infection. 1979;7 Suppl 4:S401-3. doi: 10.1007/BF01639021. Infection. 1979. PMID: 389814 Clinical Trial.
-
Coordinated multicenter study of norfloxacin versus trimethoprim-sulfamethoxazole treatment of symptomatic urinary tract infections. The Urinary Tract Infection Study Group.J Infect Dis. 1987 Feb;155(2):170-7. doi: 10.1093/infdis/155.2.170. J Infect Dis. 1987. PMID: 2879872 Clinical Trial.
-
Trimethoprim alone in the treatment of urinary tract infections: eight years of experience in Finland.Rev Infect Dis. 1982 Mar-Apr;4(2):358-65. doi: 10.1093/clinids/4.2.358. Rev Infect Dis. 1982. PMID: 7051235 Review.
-
Trimethoprim alone for treatment of urinary tract infection.Rev Infect Dis. 1982 Mar-Apr;4(2):366-71. doi: 10.1093/clinids/4.2.366. Rev Infect Dis. 1982. PMID: 7051236 Review.
Cited by
-
Clinical pharmacokinetics of co-trimazine.Clin Pharmacokinet. 1986 Sep-Oct;11(5):372-86. doi: 10.2165/00003088-198611050-00003. Clin Pharmacokinet. 1986. PMID: 3536256 Review.
-
Safety of sulfamethoxazole-trimethoprim for the treatment of bacterial infection in outpatient settings: A systematic review and meta-analysis with active comparator disproportionality analysis.Br J Clin Pharmacol. 2025 Jun;91(6):1632-1648. doi: 10.1111/bcp.70051. Br J Clin Pharmacol. 2025. PMID: 40441678 Free PMC article.
-
Safety of sulfamethoxazole-trimethoprim for the treatment of bacterial infection in outpatient settings: A systematic review and meta-analysis with active comparator disproportionality analysis.Br J Clin Pharmacol. 2025 Jun;91(6):1632-1648. doi: 10.1002/bcp.70051. Epub 2025 Mar 24. Br J Clin Pharmacol. 2025. PMID: 40129122 Free PMC article.
-
Co-trimoxazole (trimethoprim-sulfamethoxazole): an updated review of its antibacterial activity and clinical efficacy.Drugs. 1982 Dec;24(6):459-518. doi: 10.2165/00003495-198224060-00002. Drugs. 1982. PMID: 6759092 Review. No abstract available.
-
Trimethoprim/sulphonamide: concluding remarks.Infection. 1979;7 Suppl 4:S417-8. doi: 10.1007/BF01639026. Infection. 1979. PMID: 511355 No abstract available.